Clinical Trial Update: Study of Infigratinib in Children With Achondroplasia [Phase 2]

View source ↗

Summary

This update notes that the Phase 2 trial of Infigratinib in children with achondroplasia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achondroplasia

Drugs mentioned

• Infigratinib (infigratinib)

Snippet

Sponsor: QED Therapeutics, a BridgeBio company | Conditions: Achondroplasia | Phase 2 | Status: COMPLETED